VKTX
NASDAQViking Therapeutics Inc.
News · 26 weeks43-25%
2025-12-142026-06-07
Mix2190d
- Other7(33%)
- SEC Filings5(24%)
- Insider3(14%)
- Analyst3(14%)
- Earnings3(14%)
Latest news
25 items- INSIDERSEC Form 4 filed by Chief Medical Officer Chen Hubert C4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chen Hubert C3 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- ANALYSTLake Street initiated coverage on Viking Therapeutics with a new price targetLake Street initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $89.00
- ANALYSTTruist resumed coverage on Viking Therapeutics with a new price targetTruist resumed coverage of Viking Therapeutics with a rating of Buy and set a new price target of $83.00
- SECViking Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June. Details of the company's participation are as follows:William Blair 46th Annual Growth Stock ConferenceDetails: Viking management will deliver a corporate presentation, followed by a breakout session, and partic
- PRNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE:S
- PRViking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented in a second poster at the conferenceSAN DIEGO, May 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today presented additional data from its Phase 2 VENTURE-Oral
- PRViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viki
- SECSEC Form 10-Q filed by Viking Therapeutics Inc.10-Q - Viking Therapeutics, Inc. (0001607678) (Filer)
- SECViking Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateConference call scheduled for 4:30 p.m. ET today-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled ---- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 ---- VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26 ---- IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Expected 2Q26 ---- Strong Quarter-End Cash Position of $603 Million --SAN DIEGO, April 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial resu
- PRThe Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialIssued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi
- PRViking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We
- PRViking Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO, April 10, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will attend multiple upcoming investor conferences. Details of the company's participation are as follows:Raymond James Biotech/BioPharma Conference 2026Details: Viking management will participate in 1-on-1 meetingsConference Date: April 14, 2026Location: New York, NYPiper Sandler Spring Biopharma Symposium 2026Details: Viking
- SECSEC Form DEFA14A filed by Viking Therapeutics Inc.DEFA14A - Viking Therapeutics, Inc. (0001607678) (Filer)
- SECSEC Form DEF 14A filed by Viking Therapeutics Inc.DEF 14A - Viking Therapeutics, Inc. (0001607678) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.SCHEDULE 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
- ANALYSTWolfe Research initiated coverage on Viking TherapeuticsWolfe Research initiated coverage of Viking Therapeutics with a rating of Peer Perform
- PRViking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK273578-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 DiabetesSAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.
- INSIDERSEC Form 4 filed by Viking Therapeutics Inc.4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- PRViking Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. Details of the company's participation are as follows:Leerink Partners Global Healthcare Conference 2026Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 8-11, 2026Fireside Chat Timing: 10:40 – 11:10 a.m. Eastern
- SECSEC Form 10-K filed by Viking Therapeutics Inc.10-K - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateConference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended
- SECViking Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
VKTX FAQ
7 questionsWhat does Viking Therapeutics Inc. do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of...Where does VKTX stock trade?
Viking Therapeutics Inc. (VKTX) is listed on NASDAQ.What sector and industry is VKTX in?
Viking Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Viking Therapeutics Inc. go public?
Viking Therapeutics Inc. (VKTX) completed its IPO in 2015.What are analysts saying about VKTX?
Viking Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy on 2026-05-28. Recent price targets range from $3000.00 to $3800.00.What companies are similar to VKTX?
Notable peers in the same industry include LGND (Ligand Pharmaceuticals Incorporated), JNCE (Jounce Therapeutics Inc.), CBAY (CymaBay Therapeutics Inc.), ALRN (Aileron Therapeutics Inc.). Compare VKTX side-by-side with any of them on Quantisnow.How can I track VKTX on Quantisnow?
Quantisnow aggregates Viking Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VKTX to receive live email and push alerts on every new disclosure.